Search Results
Active Filters
Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.
Apr 17, 2026, 20:30 ET Antengene Presents Three Novel Programs at AACR 2026, Highlighting Next-Generation ADC and AnTenGager® TCEs
CDH6-targeted TCE candidate.ATG-112 (ALPPL2 x CD3 TCE)Title: ATG-112, a novel ALPP/G x CD3 bispecific T cell engager, for the treatment of ALPP/G+ solid tumorsAbstract Number: 1620Session Category: ImmunologySession
More news about: Antengene Corporation Limited
Mar 17, 2026, 20:30 ET Antengene to Present on Three Preclinical Programs at AACR 2026, Highlighting Next-Generation ADCs and AnTenGager™ TCEs
CDH6-expressing solid tumors.ATG-112 (ALPPL2 x CD3 TCE)Title: ATG-112, a novel ALPP/G x CD3 bispecific T cell engager, for the treatment of ALPP/G+ solid tumorsAbstract Number: 1620Session Category: ImmunologySession
More news about: Antengene Corporation Limited